Use of CXCL9 as a Biomarker of Acthar Efficacy

Phase 4 Terminated 2 enrolled University of California, San Francisco Mallinckrodt · collab

NaSingle-groupOpen-labelTreatment

Summary

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

Timeline

Start: 2022-11-03
Primary completion: 2025-01-31
Completion: 2025-01-31

Outcome

Outcome not reported

Stopped: “sponsor closed study down”

Publications

Background Su R, Li MM, Bhakta NR, Solberg OD, Darnell EP, Ramstein J, Garudadri S, Ho M, Woodruff PG, Koth LL. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J. 2014 Oct;44(4):985-93. doi: 10.1183/09031936.00039714. Epub 2014 Aug 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acthar	Peptide	80 iu	Intramuscular